Latest News

Due to its immunosuppressive tumor microenvironment, prostate cancer has historically been difficult to treat with immuno-oncology approaches. Other than pembrolizumab, which is now regulatory-approved for all microsatellite instability (MSI)-high and tumor mutational burden (TMB)-high advanced solid tumors, sipuleucel-T is the only immunotherapeutic agent approved by the US Food and Drug Administration (FDA) for prostate cancer.

This paper provides an overview of the multifarious role of nursing in enhanced recovery after surgery (ERAS) in advanced bladder cancer surgery with procedure-specific recommendations in radical cystectomy pathways.

We propose a bladder cancer patient-centered, interdisciplinary collaboration model of care adapted from an earlier model by Black, Dornan, and Allegrante (1986). The Bladder Patient-Centered Interdisciplinary Team (BPIT) model provides a conceptual foundation for assembling interdisciplinary teams and emphasizes the patient as an active participant in treatment and member of the care team, along with […]

The current treatment paradigm for muscle-invasive bladder cancer (MIBC) consists of cisplatin-based neoadjuvant chemotherapy followed by local definitive therapy, or local definitive therapy alone for cisplatin-ineligible patients.

Bladder cancer is the ninth most common type of cancer worldwide. In the past, radical cystectomy via open surgery has been considered the gold-standard treatment for muscle invasive bladder cancer.

Neal Shore: Welcome everyone to implementation for “A Step Towards Personalized Medicine, PET-PSMA Imaging in Prostate Cancer”. This is one of a multi-part series. I’m Neal Shore, the Medical Director of Carolina Urologic Research Center, and it’s a great privilege for me to introduce our speaker for this program today. My good friend and colleague, […]

Phillip Koo: Hi, I’m Phillip Koo. I’m a nuclear radiologist for Banner MD Anderson in Phoenix, Arizona. Welcome to our special program titled “A Step Towards Personalized Medicine: PET-PSMA Imaging in Prostate Cancer”. We’re very fortunate to have with us today, Dr. Andrei Iagaru, who’s the Chief of Nuclear Medicine and Professor of Radiology at […]

Collaboration will focus on UGN-302 as an investigational treatment for high-grade non-muscle invasive bladder cancer San Francisco, CA (UroToday.com) — UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center announced a strategic three-year collaboration agreement to advance […]

Uncovering the natural history of prostate cancer in data from millions of patient lives across the globe PIONEER, EHDEN and OHDSI join forces to study the clinical management of prostate cancer in a virtual studyathon Prostate cancer is a major disease affecting more than 2 million men in Europe alone, and has now become the […]

The prognostic classification system of the International Germ Cell Cancer Cooperative Group (IGCCCG) for testicular germ cell tumors is based on the histological subtype, location of the primary tumor, extent of metastatic spread and prechemotherapy tumor marker serum concentrations.